Supervivencia en pacientes con cáncer pulmonar de células no pequeñas vacunados con CIMAvax-EGF

An observational, descriptive and cross-sectional study in a first moment, and cohort analytic in a second time, of 95 patients with  non - small cell lung cancer in advanced stages, assisted at “Saturnino Lora Torres” Teaching Clinical Surgical Provincial Hospital  and in 4 polyclinics of  Santiago de Cuba, was carried out during the period 2006-2013, in order to estimate the survival in them after the vaccination with CIMAvax-EGF and to identify the factors associated to the mortality, for which Kaplan-Meier method and Cox regression were used, respectively.  The global survival in 2 years was 20.7%, with a median of 13 months, as long as the survival a year after applying the vaccine was 36.5%.  On the other hand, in the stage IIIB, the favorable response to the first line treatment, the chemotherapy-radiotherapy-vaccine combination and the immunization in 4 or more occasions, facilitated a significantly higher survival.  The unfavorable reaction to the first therapeutic line constituted a prediction factor of death risk increase in the population affected.